The 2026 Dyslipidemia Guideline: Why LDL-C Is Not Enough
Introduction
For decades, cardiovascular risk assessment has centered on one familiar number: LDL cholesterol. When LDL-C was elevated, concern increased. When it fell within the laboratory reference range, patients often assumed their arteries were safe. But cholesterol concentration and the number of cholesterol-carrying particles in the bloodstream are not always the same—and that difference can leave meaningful cardiovascular risk undetected.
The new 2026 ACC/AHA multisociety guideline on the management of dyslipidemia reflects a more complete approach. LDL-C remains an important and proven marker, but the guideline expands the role of apolipoprotein B, or ApoB, for identifying atherogenic particle burden that may be underestimated by a standard lipid panel. It also recommends measuring lipoprotein(a), or Lp(a), at least once during adulthood because this largely inherited risk factor is not included in routine cholesterol testing.
This distinction matters because atherosclerosis is driven by lipoprotein particles entering and becoming retained within the arterial wall. LDL-C estimates how much cholesterol is carried inside LDL particles, while ApoB provides an approximation of how many potentially atherogenic particles are circulating. Two people can therefore have an identical LDL-C level but a very different number of particles—and potentially a different level of cardiovascular risk.
This mismatch is especially relevant in people with elevated triglycerides, metabolic syndrome, insulin resistance or type 2 diabetes. In these conditions, LDL particles may carry less cholesterol individually, allowing LDL-C to appear acceptable even when the total number of atherogenic particles remains high. The guideline notes that ApoB testing can improve risk assessment, particularly when triglycerides exceed 200 mg/dL, diabetes is present or LDL-C has already been lowered below 70 mg/dL.
Lp(a) reveals a different kind of hidden risk. Its concentration is determined primarily by genetics, usually remains relatively stable and cannot be inferred from LDL-C. Elevated Lp(a) is associated with atherosclerotic cardiovascular disease and calcific aortic valve disease. Because most people have never had it measured, the guideline’s recommendation for at least one adult test represents an important change in preventive cardiovascular care.
The central message is not that LDL-C no longer matters. It is that LDL-C does not always tell the whole story. Combining the standard lipid panel with carefully selected markers such as ApoB and Lp(a) can help patients and clinicians see cardiovascular risk more clearly—before a heart attack, stroke or other cardiovascular event becomes the first warning sign.
What Is Dyslipidemia?
Dyslipidemia describes an unhealthy pattern of lipids or lipoproteins circulating in the blood. It can include elevated LDL cholesterol, high triglycerides, low HDL cholesterol, an excessive number of atherogenic particles or inherited abnormalities such as elevated Lp(a). A person may have one of these findings or several at the same time.
Although cholesterol is often presented as the problem, cholesterol itself is essential. The body uses it to maintain cell membranes and produce steroid hormones, bile acids and vitamin D. Because cholesterol and triglycerides cannot dissolve freely in blood, they must be transported inside particles called lipoproteins. These include LDL, very-low-density lipoprotein remnants and Lp(a), among others.
The particles most closely connected with atherosclerosis contain a structural protein called apolipoprotein B. Each atherogenic particle carries one ApoB molecule, which allows an ApoB blood test to approximate the total number of these particles in circulation. When an ApoB-containing particle crosses the arterial lining and becomes trapped, it can promote inflammation, plaque formation and the gradual narrowing of an artery.
LDL-C measures something different: the amount of cholesterol being carried inside LDL particles. It does not directly count those particles. Imagine two highways transporting the same amount of cargo. One may have a small number of fully loaded trucks, while the other has many partially loaded trucks. The total cargo is identical, but the second highway is exposed to far more vehicles. Similarly, two people with the same LDL-C can have substantially different ApoB levels.
This discrepancy, known as discordance, occurs frequently in people with insulin resistance, type 2 diabetes, abdominal obesity or elevated triglycerides. Their LDL particles may contain less cholesterol, so more particles are required to transport a given amount. LDL-C may therefore look unremarkable while ApoB reveals a higher concentration of particles capable of entering the arterial wall. The American Heart Association explains that this is one reason ApoB can provide a clearer assessment when a standard lipid panel may underestimate risk.
Dyslipidemia should therefore be understood as more than “high cholesterol.” It is a disorder of lipid transport involving the concentration, composition and number of circulating lipoproteins. The 2026 guideline recognizes this broader biology by retaining LDL-C as a central treatment marker while expanding the use of ApoB and Lp(a) to uncover risks that cholesterol concentration alone may miss.
Key takeaway: LDL-C estimates the cholesterol carried inside LDL particles, while ApoB reflects how many atherogenic particles are circulating. Both measurements can be useful, but they answer different questions.
What Changed in the 2026 Guideline?
The 2026 ACC/AHA multisociety guideline replaces the 2018 cholesterol guideline and introduces a broader approach to cardiovascular prevention. Rather than relying primarily on LDL-C and a single 10-year risk estimate, it incorporates lifetime risk, additional blood markers and selective imaging to help identify people whose risk may otherwise be underestimated.
One of the most important changes is the recommendation that every adult have Lp(a) measured at least once, ideally with an initial lipid assessment. Previous guidance emphasized testing people with premature cardiovascular disease or a strong family history. The new recommendation recognizes that elevated Lp(a) is common, mostly inherited and generally invisible on a standard lipid panel. If it is never measured, many people will not know they carry this additional risk.
According to the guideline, an Lp(a) level of 125 nmol/L or greater—or 50 mg/dL or greater when reported by mass—is considered a risk-enhancing factor. Risk continues to rise as Lp(a) increases rather than suddenly appearing at one exact threshold. The guideline reports that levels above 125 nmol/L are associated with approximately 1.4 times greater atherosclerotic cardiovascular risk, while levels above 250 nmol/L are associated with at least twice the risk. Because conversions between mg/dL and nmol/L are not exact, results should be interpreted in the units reported by the laboratory.
The guideline also gives ApoB a clearer role in identifying residual lipoprotein-related risk. ApoB testing can be particularly useful in people with triglycerides above 200 mg/dL, diabetes or very low achieved LDL-C. It may also help when LDL-C and non–HDL-C have reached their treatment goals but concern remains that the number of circulating atherogenic particles is still elevated.
Importantly, the guideline does not recommend replacing the standard lipid panel with ApoB in every situation. LDL-C and non–HDL-C remain central treatment markers. ApoB is presented as an additional tool that can clarify risk when cholesterol content and particle number may be discordant. This more selective recommendation prevents ApoB from being treated as a universal substitute while acknowledging its value in metabolically complex patients.
Another major change is the adoption of the American Heart Association’s PREVENT-ASCVD equations. These equations estimate both 10-year and 30-year cardiovascular risk in adults ages 30 through 79 without known atherosclerotic cardiovascular disease or subclinical atherosclerosis. They incorporate cardiovascular, kidney and metabolic health, allowing risk discussions to extend beyond cholesterol alone.
The guideline also restores specific LDL-C treatment goals based on a person’s level of risk and expands the role of coronary artery calcium testing when the decision to begin or intensify therapy remains uncertain. Blood markers such as ApoB and Lp(a) estimate biological risk, while coronary calcium imaging can show whether calcified plaque is already present. These tools provide different but complementary information.
Taken together, the updates move cardiovascular prevention toward a more individualized model. The question is no longer simply, “Is your LDL-C high?” It is also: How many atherogenic particles are circulating? Is there an inherited Lp(a)-related risk? Are metabolic or kidney conditions increasing overall risk? And is there already evidence of plaque within the coronary arteries?
Key takeaway: The 2026 guideline preserves LDL-C as an important treatment marker but expands risk assessment through once-in-adulthood Lp(a) testing, selective ApoB measurement, the PREVENT-ASCVD calculator and coronary artery calcium imaging.
ApoB: Counting Atherogenic Particles
ApoB helps answer a question that LDL-C cannot answer directly: how many potentially atherogenic lipoprotein particles are circulating in the bloodstream?
Most particles capable of contributing to atherosclerosis carry one molecule of apolipoprotein B on their surface. These include LDL, intermediate-density lipoproteins, very-low-density lipoprotein remnants and Lp(a). Because each particle carries a single ApoB molecule, the concentration of ApoB provides a practical estimate of the total number of atherogenic particles in the blood.
This matters because cholesterol does not enter the arterial wall independently. It arrives inside a lipoprotein particle. The more ApoB-containing particles in circulation, the more opportunities those particles have to cross the arterial lining, become retained and initiate the inflammatory processes involved in plaque formation. The cholesterol carried by those particles is still important, but particle number helps describe how frequently the arterial wall is exposed.
LDL-C and ApoB often move together, but not always. Some LDL particles carry large amounts of cholesterol, while others carry relatively little. When particles contain less cholesterol, a person may need more of them to transport the same overall amount. LDL-C can therefore remain within a seemingly acceptable range while ApoB is elevated.
Consider two people with an LDL-C of 100 mg/dL. One may carry that cholesterol in a relatively small number of cholesterol-rich particles. The other may carry it in a much larger number of cholesterol-depleted particles. Their standard lipid panels could look similar, but the second person would have more ApoB-containing particles circulating and interacting with the arterial wall.
This discordance is especially common when triglyceride metabolism is disrupted. Insulin resistance increases the delivery of fatty acids to the liver and can promote the production of triglyceride-rich VLDL particles. As these particles are remodeled in circulation, they can contribute to a larger number of cholesterol-depleted LDL particles. This pattern may occur alongside elevated triglycerides, low HDL-C, abdominal obesity, fatty liver or type 2 diabetes.
For this reason, the 2026 dyslipidemia guideline identifies ApoB as particularly useful for people with triglycerides above 200 mg/dL, diabetes or LDL-C below 70 mg/dL after treatment. In these settings, LDL-C may underestimate the remaining concentration of atherogenic particles.
ApoB should not be interpreted alone. Its significance depends on a person’s medical history, existing cardiovascular disease, metabolic health and overall risk category. It also does not reveal how much of the measured risk comes specifically from Lp(a), which must be tested separately. Nevertheless, ApoB can expose residual particle-related risk that remains hidden when attention is limited to LDL-C.
Key takeaway: LDL-C measures the cholesterol inside LDL particles. ApoB estimates the total number of atherogenic particles capable of entering the arterial wall, making it especially informative when triglycerides are elevated or insulin resistance and diabetes are present.
Lp(a): The Inherited Risk Most People Never Test
Lipoprotein(a), abbreviated Lp(a), is an atherogenic particle that resembles LDL but carries an additional protein called apolipoprotein(a). This structural difference gives Lp(a) biological properties that may contribute to arterial plaque formation, inflammation and calcification of the aortic valve.
Unlike LDL-C, which can change considerably in response to diet, metabolic health and medication, Lp(a) concentration is determined primarily by genetics. Levels are usually established early in life and remain relatively stable throughout adulthood. A person can therefore exercise regularly, maintain a healthy weight and have an acceptable standard cholesterol panel while still carrying elevated Lp(a).
Family history can offer a clue, especially when a parent or sibling experienced a heart attack, stroke or aortic valve disease at an unusually young age. However, the absence of an obvious family history does not rule it out. Relatives may never have been tested, family medical histories may be incomplete, and inherited risk does not produce the same outcome in every person.
Lp(a) is also not included in a routine lipid panel. Total cholesterol, LDL-C, HDL-C and triglycerides cannot be used to predict it reliably. The only way to determine whether it is elevated is to order a specific Lp(a) blood test. This is why the 2026 dyslipidemia guideline recommends measuring Lp(a) at least once in every adult’s lifetime, ideally alongside an initial lipid assessment.
The guideline identifies an Lp(a) concentration of at least 125 nmol/L or 50 mg/dL as a cardiovascular risk-enhancing factor. However, Lp(a)-related risk exists on a continuum: it generally rises as the level increases rather than beginning suddenly at one cutoff. Laboratories may report results in either nmol/L or mg/dL, and these units should not be converted with a single universal formula because particle size varies among individuals.
An elevated result does not mean that a heart attack or stroke is inevitable. It means an important inherited risk factor should be included in the overall assessment. Clinicians may respond by paying closer attention to LDL-C, ApoB, blood pressure, diabetes, smoking, kidney function and other modifiable contributors. In selected patients, coronary artery calcium imaging may provide additional information about whether calcified coronary plaque is already present.
Because Lp(a) is largely inherited, testing can also have implications for close relatives. When a markedly elevated concentration is identified, screening parents, siblings and children may uncover other family members who could benefit from earlier cardiovascular risk assessment. This process is known as cascade screening.
Most adults will not need frequent repeat testing because Lp(a) generally remains stable. Reassessment may be considered when a physiological or medical change could meaningfully influence the result or when a clinician needs to confirm an unexpected measurement. The initial test, however, can reveal a lifelong risk factor that an ordinary cholesterol panel may have missed for years.
Key takeaway: Lp(a) is a mostly inherited cardiovascular risk factor that cannot be predicted from LDL-C or a standard lipid panel. The 2026 guideline recommends measuring it at least once during adulthood so elevated risk can be recognized and managed earlier.
When LDL-C and ApoB Disagree
LDL-C and ApoB frequently rise and fall together, but they measure different features of the lipoprotein system. LDL-C estimates the mass of cholesterol transported inside LDL particles, while ApoB reflects the number of circulating atherogenic particles. When these measurements point in different directions, the pattern is called discordance.
Discordance can appear in two main forms. A person may have relatively low LDL-C but elevated ApoB, indicating that cholesterol is distributed across a larger number of particles. Alternatively, LDL-C may be elevated while ApoB is comparatively lower, suggesting that fewer particles are carrying more cholesterol individually. These patterns may not represent the same biological exposure even when the LDL-C values are identical.
The first pattern—higher ApoB than LDL-C would suggest—is particularly important in people with insulin resistance, metabolic syndrome and type 2 diabetes. These conditions often increase triglyceride-rich VLDL production in the liver. As VLDL particles circulate and lose triglycerides, they can generate remnants and cholesterol-depleted LDL particles. The result may be a large number of atherogenic particles without a proportionate increase in LDL-C.
For example, a person may have an LDL-C of 105 mg/dL, a value that might not initially appear alarming, while also having high triglycerides, low HDL-C and elevated ApoB. Looking only at LDL-C could underestimate the number of particles repeatedly encountering the arterial wall. ApoB helps expose that residual risk.
The reverse pattern can also occur. Some people—particularly those who are lean, metabolically healthy or consuming a very-low-carbohydrate diet—may develop elevated LDL-C with less pronounced elevations in ApoB or triglycerides. This does not establish that the elevated LDL-C is harmless. It means the results should be interpreted together rather than assuming that one marker automatically overrides the others.
When LDL-C and ApoB disagree, evidence generally indicates that cardiovascular risk aligns more closely with the number of ApoB-containing particles. This makes biological sense because every atherogenic particle represents another opportunity for entry and retention within the arterial wall. Nevertheless, cardiovascular risk remains multifactorial and should also account for Lp(a), blood pressure, smoking, diabetes, kidney disease, family history and evidence of existing plaque.
Non–HDL-C can provide another useful perspective. It is calculated by subtracting HDL-C from total cholesterol and therefore captures cholesterol carried by LDL, VLDL remnants and other ApoB-containing particles. It is available from a standard lipid panel and is often more informative than LDL-C when triglycerides are elevated, although it still measures cholesterol content rather than particle number.
The 2026 guideline recognizes ApoB as a tool for resolving this uncertainty. It can be especially valuable after LDL-C and non–HDL-C goals have been reached but residual lipoprotein-related risk is still suspected. Instead of treating LDL-C as the entire story, clinicians can use ApoB to determine whether a high number of atherogenic particles remains in circulation.
Key takeaway: When LDL-C and ApoB are discordant, LDL-C may understate or overstate particle burden. ApoB clarifies how many atherogenic particles are present, but the result should still be interpreted within the person’s complete metabolic and cardiovascular profile.
Who Benefits From Advanced Lipid Testing?
A standard lipid panel remains an appropriate starting point for most adults, but it may not provide enough information for everyone. Additional testing becomes especially useful when a person’s medical history, metabolic health or family history suggests that LDL-C could be underestimating cardiovascular risk.
People with type 2 diabetes, insulin resistance or metabolic syndrome are among those most likely to benefit from ApoB testing. These conditions can increase the production of triglyceride-rich lipoproteins and create a larger number of cholesterol-depleted LDL particles. LDL-C may therefore appear normal or only mildly elevated even while the number of atherogenic particles remains high.
ApoB can also be informative when triglycerides exceed 200 mg/dL, HDL-C is low or non–HDL-C and LDL-C do not appear consistent with the rest of the metabolic picture. Abdominal obesity, fatty liver, elevated fasting insulin and impaired glucose regulation can strengthen the reason to look beyond a standard cholesterol panel.
People already receiving lipid-lowering treatment may benefit as well. LDL-C can reach its treatment goal while ApoB remains elevated, indicating residual particle-related risk. The 2026 dyslipidemia guideline specifically highlights ApoB measurement in people with cardiovascular disease, type 2 diabetes, elevated triglycerides or very low achieved LDL-C.
Lp(a) is different because the guideline recommends at least one measurement for every adult, not only those considered high risk. Testing becomes especially important when there is a personal or family history of premature heart attack, stroke, peripheral artery disease or aortic valve stenosis. It may also help explain cardiovascular disease that appears disproportionate to traditional risk factors.
Family screening deserves particular attention. Because elevated Lp(a) is largely inherited, identifying a high level in one person can provide useful information for parents, siblings and children. Testing close relatives may reveal elevated risk years before symptoms or cardiovascular events occur.
Advanced testing may also help people whose results appear reassuring but whose broader history is not. A normal LDL-C result should not automatically end the evaluation when there is diabetes, chronic kidney disease, persistent inflammation, smoking, hypertension or a strong family history. Conversely, an isolated abnormal marker should not be treated as a complete diagnosis without considering the rest of the clinical picture.
The purpose of advanced lipid testing is not to order every available marker for every patient. It is to answer specific questions that routine testing cannot resolve: Is particle burden higher than LDL-C suggests? Is an inherited Lp(a)-related risk present? Does residual risk remain despite meeting conventional cholesterol goals? Answering those questions can support a more individualized prevention strategy.
Key takeaway: ApoB is especially useful when diabetes, insulin resistance, elevated triglycerides or treated LDL-C may conceal residual particle burden. Lp(a) should be measured at least once in every adult, with particular importance in families affected by premature cardiovascular disease.
Nutrition and Metabolic Health
Advanced lipid testing does not diminish the importance of nutrition and lifestyle. Instead, it can show whether a particular strategy is improving the full cardiovascular picture or only changing one portion of the lipid panel.
Insulin resistance frequently produces a recognizable pattern: elevated triglycerides, low HDL-C, increased liver production of VLDL and a greater number of small, cholesterol-depleted LDL particles. LDL-C may not rise substantially, but ApoB and non–HDL-C can reveal that atherogenic particle burden remains elevated. This is one reason metabolic health should be evaluated alongside cholesterol.
Reducing refined carbohydrates and added sugars can improve triglycerides, glucose regulation and fatty liver, especially in people with insulin resistance. Mediterranean, lower-carbohydrate and other whole-food dietary patterns may all be effective when they reduce ultra-processed foods, improve satiety and support a healthy body composition. The most appropriate approach depends on the person’s glucose response, preferences, medications and overall medical condition.
Low-carbohydrate and ketogenic diets often lower triglycerides and raise HDL-C, but their effects on LDL-C and ApoB vary considerably. Some people experience little change, while others develop substantial elevations. A favorable triglyceride-to-HDL ratio does not automatically neutralize an elevated ApoB concentration, just as an elevated LDL-C should not be interpreted without considering ApoB, Lp(a), inflammation, blood pressure and existing plaque.
Dietary fat quality can also affect the response. Replacing a portion of saturated fat with unsaturated fats from foods such as olive oil, avocado, nuts, seeds and fish may lower LDL-C and ApoB in responsive individuals. However, dietary changes should be evaluated with follow-up testing rather than assumed to produce the same result in everyone.
Weight loss can improve dyslipidemia when excess adipose tissue is contributing to insulin resistance. As insulin sensitivity improves, the liver may release fewer triglyceride-rich VLDL particles, reducing triglycerides and potentially lowering ApoB. Resistance training and aerobic activity provide additional benefits by improving glucose disposal, blood pressure, cardiorespiratory fitness and body composition—even when weight loss is modest.
Lp(a) behaves differently. Because it is primarily genetically determined, diet and exercise usually have limited effects on its concentration. That does not make lifestyle irrelevant. A person with elevated Lp(a) can still reduce total cardiovascular risk by addressing smoking, hypertension, diabetes, elevated ApoB and other modifiable factors. The inherited risk may remain, but the environment surrounding it can change.
The 2026 dyslipidemia guideline supports a heart-healthy dietary pattern, regular physical activity and reduced exposure to tobacco as foundations of prevention. Medication may still be appropriate depending on the level of risk, but lifestyle and metabolic health remain essential parts of the strategy.
Key takeaway: Improving insulin sensitivity can reduce triglyceride-rich particles and ApoB, but lipid responses vary by person and dietary pattern. Lp(a) usually changes little with lifestyle, so elevated levels make control of other cardiovascular risks even more important.
How Results Guide Treatment
ApoB and Lp(a) testing are valuable only when the results change how risk is interpreted or managed. Neither marker should be treated in isolation, and an abnormal value does not automatically mean that every patient needs medication. The next step depends on the person’s overall cardiovascular risk, metabolic health, family history and evidence of existing atherosclerosis.
The 2026 guideline restores specific LDL-C and non–HDL-C treatment goals. For adults at borderline or intermediate risk of a first cardiovascular event, the LDL-C goal is generally below 100 mg/dL. For those at high risk, the goal is below 70 mg/dL. In people with established atherosclerotic cardiovascular disease who remain at very high risk, the goal is below 55 mg/dL. These are treatment goals rather than universal definitions of a “normal” LDL-C level.
When ApoB remains elevated despite LDL-C and non–HDL-C reaching their goals, the result can reveal residual particle-related risk. A clinician may respond by reviewing nutrition, medication adherence, secondary causes of dyslipidemia and whether lipid-lowering treatment should be intensified. The value of treatment depends on absolute risk: lowering ApoB is likely to provide greater absolute benefit to someone with established cardiovascular disease than to a metabolically healthy person with otherwise low short-term risk.
Statins remain the guideline’s primary medication for lowering LDL-C and reducing cardiovascular events. Depending on risk, response and tolerance, other treatments may include ezetimibe, bempedoic acid, PCSK9 inhibitors or inclisiran. These medications reduce ApoB-containing particles through different mechanisms and may be used individually or in combination when treatment goals are not reached.
Elevated Lp(a) presents a different challenge. As of 2026, there is no medication approved solely to lower Lp(a). PCSK9 inhibitors can reduce Lp(a) modestly while substantially lowering LDL-C, but they are not approved specifically as Lp(a)-targeted therapy. Several treatments designed to directly suppress Lp(a) production are under investigation, but evidence must show that lowering the laboratory value also reduces heart attacks, strokes or other clinical events.
Until dedicated therapy becomes available, identifying elevated Lp(a) can still change care. It may justify earlier and more intensive control of LDL-C, ApoB, blood pressure, diabetes and tobacco exposure. It may also influence whether coronary artery calcium imaging is used to refine risk or whether close relatives should be tested.
A high Lp(a) result should not create the impression that cardiovascular disease is unavoidable. Genetics may establish part of the risk, but the total outcome is also shaped by modifiable exposures. Conversely, a low Lp(a) level does not eliminate risk from elevated ApoB, diabetes, smoking, hypertension or existing plaque.
The objective is not to chase every laboratory number independently. It is to use each marker to build a more accurate risk profile and select interventions with a realistic likelihood of preventing disease.
Key takeaway: ApoB can reveal whether atherogenic particle burden remains elevated after conventional cholesterol goals are reached. Elevated Lp(a) currently directs attention toward earlier and more intensive management of modifiable risks while dedicated Lp(a)-lowering therapies continue to be studied.
Building a Complete Risk Profile
No single blood test can fully describe cardiovascular risk. The standard lipid panel, ApoB and Lp(a) answer different questions, while metabolic and inflammatory markers provide additional context about the environment in which atherosclerosis may develop.
A standard lipid panel remains the foundation. It measures total cholesterol, LDL-C, HDL-C and triglycerides. From these values, non–HDL-C can be calculated by subtracting HDL-C from total cholesterol. Non–HDL-C captures the cholesterol transported by LDL, VLDL remnants and other atherogenic particles, making it particularly useful when triglycerides are elevated.
ApoB adds an estimate of the total number of atherogenic particles. When ApoB is higher than expected from LDL-C, particle burden may be underestimated by the standard panel. LDL particle testing can provide further detail about particle concentration and size, although ApoB is usually a more direct and standardized way to estimate the number of atherogenic particles.
Lp(a) identifies a separate, predominantly inherited risk. Because it is not included in the standard lipid panel and cannot be calculated from other cholesterol values, it must be ordered specifically. Most adults need it measured only once, although follow-up may be appropriate in selected clinical circumstances.
High-sensitivity C-reactive protein, or hs-CRP, can add information about systemic inflammation. It is not specific to the arteries and can rise because of infection, injury or chronic inflammatory disease, so an elevated result must be interpreted carefully. When measured under stable conditions, it may help identify inflammatory risk that cholesterol markers alone do not capture.
Metabolic testing is equally important. Fasting glucose, hemoglobin A1c and fasting insulin can help identify impaired glucose regulation and insulin resistance. Triglycerides, HDL-C, liver enzymes and waist-related adiposity may provide additional clues. This broader evaluation matters because a person can have normal LDL-C while insulin resistance is increasing VLDL production, remnant particles and ApoB.
Blood pressure, kidney function, smoking history, family history and age must also be considered. If the level of risk remains uncertain after blood testing, a coronary artery calcium scan may help determine whether calcified plaque is already present. Laboratory markers estimate exposure and susceptibility; coronary calcium provides evidence of established calcified coronary atherosclerosis.
QuickLab Mobile’s cardiovascular testing options include the standard lipid panel, ApoB, Lp(a), lipoprotein fractionation, hs-CRP, fasting insulin and other cardiometabolic markers. Mobile specimen collection allows patients in Miami to complete advanced cardiovascular testing at home while their results are interpreted by the appropriate healthcare professional.
The goal is not to order the largest possible panel. Testing should be selected to answer meaningful clinical questions and avoid unnecessary cost or confusion. For many people, however, adding ApoB and a once-in-adulthood Lp(a) measurement can reveal information that a routine cholesterol test leaves unseen.
Key takeaway: A complete cardiovascular assessment combines cholesterol concentration, atherogenic particle burden, inherited risk, metabolic health and inflammation. ApoB and Lp(a) expand the picture, but they should be interpreted alongside the standard lipid panel and the person’s overall clinical risk.
Conclusion
The 2026 dyslipidemia guideline marks an important shift in cardiovascular prevention. LDL-C remains a central marker and treatment target, but it does not always reveal how many atherogenic particles are circulating or whether a person carries an inherited Lp(a)-related risk.
ApoB can uncover elevated particle burden when LDL-C appears acceptable, particularly in people with insulin resistance, type 2 diabetes or elevated triglycerides. Lp(a) provides different information by identifying a largely genetic risk factor that is absent from routine cholesterol testing. For the first time, the ACC/AHA guideline recommends that every adult have Lp(a) measured at least once.
These tests do not replace clinical judgment, nor should any single abnormal result define a person’s cardiovascular future. The most useful assessment combines the standard lipid panel with selected advanced markers, metabolic health, blood pressure, family history, lifestyle and, when appropriate, coronary artery calcium imaging.
For patients in Miami who want a more complete view of their cardiovascular health, QuickLab Mobile provides convenient at-home collection for ApoB, Lp(a), advanced lipid testing and related cardiometabolic markers. Results should be reviewed with a qualified healthcare professional who can place them within the individual’s complete risk profile.
Introduction
👉 Need a specimen collection?. Book Now
Disclaimer:
The information provided in this blog, podcast, and associated content is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. The content shared is based on reputable sources, medical literature, and expert insights, but it should not be used as a replacement for direct consultation with a licensed healthcare provider.
No Doctor-Patient Relationship: Engaging with this content does not create a doctor-patient relationship between you and QuickLabMobile or any contributors. Always consult with a qualified physician, specialist, or healthcare professional before making any medical decisions, changing your treatment plan, or starting/stopping any medications.
Not a Substitute for Medical Advice: While we strive to provide accurate and up-to-date information, medicine is constantly evolving. New research, treatments, and medical recommendations may emerge, and individual health conditions can vary. Do not rely solely on this content for health decisions. If you are experiencing symptoms, have concerns about your health, or require medical assistance, seek immediate care from a licensed medical professional.
Emergency Situations: If you are experiencing a medical emergency, such as difficulty breathing, chest pain, signs of a stroke, or any other life-threatening condition, call 911 (or your local emergency services) immediately. Do not delay seeking emergency care based on information provided here.
Liability Disclaimer: QuickLabMobile, its contributors, and any associated entities do not assume liability for any damages, harm, or adverse outcomes resulting from the use, interpretation, or misuse of the information provided in this content. You are responsible for your own healthcare decisions and should always verify information with a trusted medical professional.
External Links & References: This content may include links to external sources, medical studies, or third-party websites for further reading. These links are provided for convenience and informational purposes only. QuickLabMobile does not endorse, control, or take responsibility for the accuracy of external content. Always verify information with authoritative sources such as the CDC, NIH, WHO.
Final Note: Your health is unique, and what works for one person may not be suitable for another. Stay informed, ask questions, and always prioritize professional medical guidance
